{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-345032","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2026-08-11T21:19:43+00:00","discovered_at":"2026-08-11T21:22:00.466717+00:00","generated_at":"2026-08-11T21:22:31.174135+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eloxx Q2 2026 net loss $4.5M; cash $62M; exaluren Phase 2b to start Q3 2026","bullets":["Net loss of $4.5M ($0.39/share) for Q2 2026 vs $1.9M ($5.45/share) in Q2 2025; R&D spend up to $2.8M.","Completed $66M public offering (2.975M shares at $11.00) plus pre-funded warrants; net proceeds $58.3M.","Cash and equivalents $62.0M as of June 30, 2026; no debt; expected to fund into mid-2028.","Phase 2b trial of exaluren in Alport syndrome expected to start Q3 2026; topline data mid-2027.","EU granted orphan designation for exaluren in ADPKD; Phase 2 trial planned 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-345032","json":"https://secwatch.observer/filing/0001193125-26-345032.json","markdown":"https://secwatch.observer/filing/0001193125-26-345032.md","text":"https://secwatch.observer/filing/0001193125-26-345032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526345032/0001193125-26-345032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526345032/d167833d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T21:22:31.174135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}